Vedolizumab as induction and maintenance therapy for Crohn's disease.
By W. Sandborn, B. Feagan, P. Rutgeerts, S. Hanauer, J. Colombel, Bruce E. Sands, M. Lukáš, R. Fedorak, S. Lee, B. Bressler and 7 more. New England Journal of Medicine, 2013
2,088 citations recorded by the source corpus.
Subfields: Epidemiology, Genetics, Rheumatology
View Paper: https://www.semanticscholar.org/paper/f994d1f4f11394014f86aeef0ba49c5463bb4cf7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- The gut microbiota and inflammatory bowel disease (2014, background): “Moreover, small molecules have become available, such as the JAK inhibitor tofacitinib.(9) However, most of these treatments have significant side effects, are expensive and often prove to be ineffective.”
- Recent Advances in Aptamer Discovery and Applications (2019, background): “The examples of these drugs include trastuzumab targeting receptor tyrosine-protein kinase 2 ERBB2 implicated in ovarian and breast tumors [3] , anti-CD20 chimeric mAb rituximab developed for treating B-cell non-Hodgkin lymphoma [4] , and Vedolizumab inhibiting integrin α4β7, which plays an importan”